AbbVie (NYSE:ABBV) Stock Jumps 1.3% – Here’s What Happened

Shares of AbbVie Inc. (NYSE:ABBV) shot up 1.3% on Friday. The company traded as high as $264.06 and last traded at $263.2670. 5,540,598 shares were traded during trading, a decline of 14% from the average daily volume of 6,439,068 shares. The stock had previously closed at $259.93.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA approval expands AbbVie’s neuroscience portfolio. The FDA approved Juvmo for Parkinson’s disease, with a commercial launch targeted for October 2026. The new product could diversify growth beyond immunology and help strengthen AbbVie’s neuroscience franchise. FDA approves AbbVie’s Juvmo for Parkinson’s Disease
• Positive Sentiment: RINVOQ showed continued efficacy in vitiligo. Phase 3 Viti-Up-1 and Viti-Up-2 results showed that facial and total-body repigmentation continued to improve through week 76. Responses were also numerically higher when RINVOQ was combined with narrowband UV-B phototherapy, supporting the drug’s potential for broader dermatology growth. AbbVie Presents Long-Term RINVOQ Data
• Positive Sentiment: Pipeline activity remains active. AbbVie provided an update on an ongoing study evaluating Venetoclax in acute myeloid leukemia, while recent dermatology data and the Juvmo approval reinforce investor expectations for continued product-led growth. AbbVie’s Venetoclax AML Study Update
• Neutral Sentiment: Third-quarter results are approaching. AbbVie will report third-quarter 2026 results before the market opens on October 30, giving investors a near-term catalyst to assess Juvmo expectations, RINVOQ and Skyrizi momentum, and overall earnings guidance. AbbVie Third-Quarter 2026 Earnings Conference Call
• Negative Sentiment: Valuation and legacy-product pressure remain risks. AbbVie’s strong recent performance has raised concerns about whether its valuation fully reflects future cash-flow growth. Humira erosion, competitive pressure, and the need for newer products such as Juvmo to scale commercially could limit further upside.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Piper Sandler raised their price target on AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. Royal Bank Of Canada upped their price objective on shares of AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a report on Friday, July 10th. HSBC increased their price objective on shares of AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $225.00 target price (up from $203.00) on shares of AbbVie in a report on Tuesday, June 23rd. Finally, Bank of America reiterated a “buy” rating on shares of AbbVie in a research note on Tuesday, September 8th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $272.66.

AbbVie Stock Up 1.3%

The firm has a market capitalization of $465.14 billion, a price-to-earnings ratio of 74.37, a P/E/G ratio of 1.19 and a beta of 0.24. The company’s 50 day moving average is $257.79 and its 200 day moving average is $234.39.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter in the previous year, the firm posted $2.97 EPS. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, analysts expect that AbbVie Inc. will post 14.05 EPS for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a yield of 2.6%. AbbVie’s payout ratio is currently 195.48%.

Insider Buying and Selling at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.06% of the company’s stock.

Institutional Investors Weigh In On AbbVie

Several institutional investors and hedge funds have recently bought and sold shares of ABBV. ACT Advisors LLC. grew its holdings in shares of AbbVie by 2.5% during the second quarter. ACT Advisors LLC. now owns 1,688 shares of the company’s stock worth $425,000 after purchasing an additional 41 shares in the last quarter. Willner & Heller LLC lifted its position in AbbVie by 0.7% during the second quarter. Willner & Heller LLC now owns 5,852 shares of the company’s stock valued at $1,472,000 after purchasing an additional 43 shares during the last quarter. B.O.S.S. Retirement Advisors LLC lifted its position in AbbVie by 3.1% during the second quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company’s stock valued at $359,000 after purchasing an additional 43 shares during the last quarter. Fielder Capital Group LLC grew its stake in AbbVie by 1.7% in the 2nd quarter. Fielder Capital Group LLC now owns 2,532 shares of the company’s stock worth $637,000 after buying an additional 43 shares in the last quarter. Finally, Guardian Wealth Advisors LLC NC increased its holdings in shares of AbbVie by 0.4% in the 2nd quarter. Guardian Wealth Advisors LLC NC now owns 11,906 shares of the company’s stock worth $2,996,000 after buying an additional 43 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.